Figure 1From: Selective inhibitors of nuclear export (SINE) in hematological malignancies The chemical structures of selective inhibitors of nuclear export (SINE). Selinexor (KPT-330) is the first-in-human SINE agent in clinical trials. It is an oral small molecule inhibitor targeting CRM1/XPO1, the major nuclear-cytoplasmic exportin.Back to article page